Results of Phase 2 research
APX3330, a First-in-Class Ref-1 Inhibitor for Diabetic Ocular Diseases Affecting the Retina, Added to Ocuphire Portfolio of Ophthalmic Drug Candidates
Data from Two Recently Completed Nyxol® Phase 2b Studies Accepted for Presentation at ARVO 2020 Conference
Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications.
APX3330 is a first-in-class, orally-administered, small molecule drug candidate that selectively targets and inhibits the Ref-1 (reduction-oxidation effector factor-1) protein, a novel upstream regulator of critical transcription factors controlling inflammatory and angiogenesis pathways that are implicated in diabetic retinopathy (DR) and diabetic macular edema (DME). DR and DME are common diabetic complications that arise due to damage to small blood vessels within the eye, causing leakage, oxygen starvation and abnormal vessel growth that progressively obstructs vision, leading to blindness. APX3330 may improve eye health in diabetics by reducing inflammation, hypoxia signaling, and abnormal angiogenesis.
With nearly 8 million DR patients and another 750,000 DME patients in the U.S., there is a large unmet market opportunity for new treatments to complement existing therapies. The primary therapies today are intravitreal anti-VEGF antibodies (Lucentis® and Eylea®) with sales over $10 billion worldwide, which are given as injections into the white (sclera) of the eye every one to three months. Earlier treatment options to prevent or delay vision loss for patients with diabetic eye disease are important. APX3330’s safety profile, pharmacokinetic properties, and molecular target engagement data observed in clinical trials and its drug exposure in the retina seen in mouse models, combined with a unique oral tablet formulation, suggest its potential to reduce the frequency of anti-VEGF treatments and increase compliance for better outcomes.
APX3330 has been dosed twice-a-day in over 400 subjects across 11 Phase 1 and Phase 2 trials, with few systemic adverse events reported and clinical data that supports chronic administration. Dr. Mark R. Kelley, Associate Director of Basic Science, Indiana University Simon Cancer Center, discovered and characterized the Ref-1 target and its mechanisms and led the team that identified APX3330 as an effective Ref-1 inhibitor. Dr. Kelley co-founded Apexian, which initially explored APX3330’s utility in advanced solid tumors, with recent presentations at ASCO and AACR, and then ophthalmic and other clinical indications. Based on APX3330’s clinical and pre-clinical data, Ocuphire plans to begin a Phase 2 proof-of-concept study in non-proliferative DR and DME in 2020.
“We are very pleased to enter into this licensing agreement and partnership with Ocuphire to advance APX3330 into Phase 2 clinical ophthalmology trials for DR and DME. The expertise, experience and leadership of the Ocuphire team is a major factor for our entering into this partnership,” said Dr. Mark R. Kelley, Chief Scientific Officer of Apexian. “APX3330 is an oral drug that has demonstrated a promising safety profile, predicted PK and target engagement on APE1/Ref-1 in previous clinical trials. The partnership with Ocuphire will also allow us to develop the extensive pipeline of Ref-1 inhibitors including APX2009 for future ophthalmology therapeutic interventions including in Age-Related Macular Degeneration”……
Read more: https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ocuphire.com&esheet=52162046&newsitemid=20200122005250&lan=en-US&anchor=www.ocuphire.com&index=4&md5=6f100f9fe0f97c74dad913be14dc2578